The risk or severity of adverse effects can be increased when Olanzapine is combined with Dextropropoxyphene. The therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Olanzapine. Olanzapine may increase the QTc-prolonging activities of Lumefantrine. The risk or severity of adverse effects can be increased when Delorazepam is combined with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Chlorprothixene. Olanzapine can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy. The risk or severity of adverse effects can be increased when Olanzapine is combined with Heroin. The metabolism of Olanzapine can be decreased when combined with Desipramine. The therapeutic efficacy of Miglustat can be decreased when used in combination with Olanzapine. The risk or severity of adverse effects can be increased when Methylene blue is combined with Olanzapine. The serum concentration of Olanzapine can be decreased when it is combined with Osimertinib. The risk or severity of adverse effects can be increased when Olanzapine is combined with Canertinib. The risk or severity of adverse effects can be increased when Olanzapine is combined with Butorphanol. 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic activities of Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Fentanyl. The serum concentration of Dabrafenib can be decreased when it is combined with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Fencamfamine. The metabolism of Tacrolimus can be decreased when combined with Olanzapine. The risk or severity of adverse effects can be increased when Selegiline is combined with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Glutethimide. The serum concentration of Olanzapine can be increased when it is combined with Deferasirox. The therapeutic efficacy of Levodopa can be decreased when used in combination with Olanzapine. Olanzapine may increase the QTc-prolonging activities of Toremifene. The risk or severity of adverse effects can be increased when Olanzapine is combined with Amoxapine. The serum concentration of Fluvastatin can be increased when it is combined with Olanzapine. The risk or severity of adverse effects can be increased when Acepromazine is combined with Olanzapine. Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Olanzapine. Safrazine may increase the serotonergic activities of Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Chloroprocaine. Olanzapine may increase the QTc-prolonging activities of Paliperidone. The risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Pomalidomide. The risk or severity of adverse effects can be increased when Propericiazine is combined with Olanzapine. Olanzapine may increase the QTc-prolonging activities of Escitalopram. Olanzapine may increase the QTc-prolonging activities of Methadone. The risk or severity of adverse effects can be increased when Olanzapine is combined with Propoxycaine. Olanzapine may increase the QTc-prolonging activities of Asenapine. The risk or severity of adverse effects can be increased when Camazepam is combined with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Meclizine. The risk or severity of adverse effects can be increased when Lormetazepam is combined with Olanzapine. The therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Olanzapine. Olanzapine may increase the antipsychotic activities of Sulpiride. The risk or severity of adverse effects can be increased when Almotriptan is combined with Olanzapine. The therapeutic efficacy of Acarbose can be decreased when used in combination with Olanzapine. Benmoxin may increase the serotonergic activities of Olanzapine. The risk or severity of adverse effects can be increased when Rasagiline is combined with Olanzapine. Olanzapine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Levomethadyl Acetate. The risk or severity of adverse effects can be increased when Clonazepam is combined with Olanzapine. Duloxetine may increase the serotonergic activities of Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Dextromoramide. The risk or severity of adverse effects can be increased when Olanzapine is combined with Ezogabine. Olanzapine can cause a decrease in the absorption of Pazopanib resulting in a reduced serum concentration and potentially a decrease in efficacy. The metabolism of Olanzapine can be decreased when combined with Tranylcypromine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Felbamate. Olanzapine may increase the QTc-prolonging activities of Primaquine. The serum concentration of Olanzapine can be decreased when it is combined with Peginterferon alfa-2b. The risk or severity of adverse effects can be increased when Olanzapine is combined with clomethiazole. The risk or severity of adverse effects can be increased when Olanzapine is combined with Dihydroetorphine. The metabolism of Olanzapine can be decreased when combined with Clotrimazole. The risk or severity of adverse effects can be increased when Ergonovine is combined with Olanzapine. The metabolism of Olanzapine can be decreased when combined with Mirabegron. The metabolism of Olanzapine can be decreased when combined with Paroxetine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Aceprometazine. The therapeutic efficacy of Sulodexide can be decreased when used in combination with Olanzapine. Olanzapine may increase the QTc-prolonging activities of Quinine. The metabolism of Olanzapine can be decreased when combined with Clobazam. Olanzapine can cause a decrease in the absorption of Delavirdine resulting in a reduced serum concentration and potentially a decrease in efficacy. The risk or severity of adverse effects can be increased when Olanzapine is combined with Etifoxine. Caroxazone may increase the serotonergic activities of Olanzapine. The metabolism of Olanzapine can be decreased when combined with Fluvoxamine. The risk or severity of adverse effects can be increased when Linezolid is combined with Olanzapine. The risk or severity of adverse effects can be increased when Nicergoline is combined with Olanzapine. Olanzapine may increase the QTc-prolonging activities of Citalopram. The risk or severity of adverse effects can be increased when Olanzapine is combined with Ethyl chloride. The risk or severity of adverse effects can be increased when Temazepam is combined with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Pethidine. The risk or severity of adverse effects can be increased when Pirenzepine is combined with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Clidinium. Olanzapine may decrease the stimulatory activities of Amphetamine. The risk or severity of adverse effects can be increased when Lorazepam is combined with Olanzapine. The serum concentration of Mevastatin can be increased when it is combined with Olanzapine. The metabolism of Olanzapine can be decreased when combined with Lobeglitazone. Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Olanzapine. The risk or severity of adverse effects can be increased when Fludiazepam is combined with Olanzapine. Olanzapine can cause an increase in the absorption of Risedronate resulting in an increased serum concentration and potentially a worsening of adverse effects. Olanzapine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Olanzapine. The metabolism of Olanzapine can be decreased when combined with Cimetidine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Pipamperone. The risk or severity of adverse effects can be increased when Oxazepam is combined with Olanzapine. Olanzapine may increase the QTc-prolonging activities of Ondansetron. The risk or severity of adverse effects can be increased when Olanzapine is combined with Fluspirilene. The risk or severity of adverse effects can be increased when Perazine is combined with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Adipiplon. Phenoxypropazine may increase the serotonergic activities of Olanzapine. Olanzapine may increase the QTc-prolonging activities of Ziprasidone. Olanzapine may increase the QTc-prolonging activities of Dolasetron. The risk or severity of adverse effects can be increased when SJG-136 is combined with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Sufentanil. Olanzapine may decrease the stimulatory activities of Pseudoephedrine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Cyclobenzaprine. Olanzapine may decrease the stimulatory activities of Mephentermine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Pramocaine. The therapeutic efficacy of Alogliptin can be decreased when used in combination with Olanzapine. The risk or severity of adverse effects can be increased when Morphine is combined with Olanzapine. Buspirone may increase the serotonergic activities of Olanzapine. The therapeutic efficacy of Glibornuride can be decreased when used in combination with Olanzapine. Olanzapine may increase the QTc-prolonging activities of Moxifloxacin. The risk or severity of adverse effects can be increased when Olanzapine is combined with Vigabatrin. The therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Dapiprazole. The therapeutic efficacy of Castanospermine can be decreased when used in combination with Olanzapine. Olanzapine may increase the QTc-prolonging activities of Granisetron. Olanzapine may increase the QTc-prolonging activities of Bedaquiline. The therapeutic efficacy of Glyburide can be decreased when used in combination with Olanzapine. Olanzapine may decrease the stimulatory activities of Diethylpropion. The risk or severity of adverse effects can be increased when Olanzapine is combined with Trazodone. The metabolism of Olanzapine can be decreased when combined with Cholecalciferol. Octamoxin may increase the serotonergic activities of Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Ramelteon. The serum concentration of Bosutinib can be decreased when it is combined with Olanzapine. The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Chloral hydrate. The risk or severity of adverse effects can be increased when Olanzapine is combined with Loprazolam. The risk or severity of adverse effects can be increased when Olanzapine is combined with Remoxipride. Olanzapine may increase the QTc-prolonging activities of Anagrelide. The therapeutic efficacy of Repaglinide can be decreased when used in combination with Olanzapine. The risk or severity of adverse effects can be increased when Butabarbital is combined with Olanzapine. The risk or severity of adverse effects can be increased when Fluphenazine is combined with Olanzapine.